CD274 and non-small cell lung carcinoma: Expedited approval of the immunotherapy drug pembrolizumab has been granted for NSCLC patients whose tumors express PD-L1 (>50% staining as verified by an FDA-approved test) at the advanced stage or with unresectable tumors.[60]